Leerink Partners Rates uniQure (QURE) buy, $70 Price Target

Analyst Joseph Schwartz keeps a buy rating and a $70.00 price target on the biotechnology company, a 45.06% upside from the current price.

By TradeTexts Research Desk · Published Jun 18, 2026, 12:01 PM EDT · Updated Jun 24, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Leerink Partners rated uniQure N.V. ($QURE) "buy" with a $70 price target on June 18, 2026.

Since the rating, $QURE is up 6.1% after 1 week, down 14.2% after 1 month and down 53.0% to date (from the $46.29 close on Jun 18, 2026).

QURE uniQure N.V.

$21.78 -6.88% year to date

Daily close · Oct 16, 2026

Key Points

Leerink Partners reiterates its buy rating on uniQure N.V. with a $70.00 price target, highlighting confidence in the firm's gene therapy pipeline.
Leerink Partners's $70 price target implies 45.06% upside from uniQure N.V.'s ($QURE) current $48.26 share price.
The stock traded at $48.26 on Thursday, sitting within a wide 52-week trading range that spans from $8.73 up to $71.50.
Recent insider activity shows a mix of transactions, including a purchase and a planned sale by Chief Executive Officer Matthew Kapusta in late June.

Get $QURE trade alerts by text

We text you when insiders, Congress or big funds trade $QURE. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated uniQure N.V. alert may contain errors. Disclosures

Leerink Partners Backs uniQure's Long-Term Potential

Leerink Partners analyst Joseph Schwartz reiterated a buy rating on uniQure N.V. (NASDAQ: QURE) on June 18, 2026. The firm set its price target on the clinical-stage biotechnology company at $70.00. This assessment reflects continued confidence in the company's progress as it develops gene therapies for patients suffering from rare and devastating genetic conditions.

The $70.00 price target from Leerink Partners suggests significant room for growth from the stock's recent trading levels. The firm's positive outlook comes as uniQure continues to progress its clinical pipeline, including its lead candidate for Huntington's disease, AMT-130, which is currently in Phase I/II clinical trials.

Where uniQure Stock Stands Today

On Thursday, shares of uniQure traded at $48.26. The stock has experienced considerable volatility over the past year, charting a 52-week low of $8.73 and a 52-week high of $71.50. This wide pricing band is typical for mid-sized biotechnology firms whose valuations heavily depend on clinical trial data readouts and regulatory updates.

The company has a market capitalization of approximately $1.56 billion. Looking at its moving averages, the stock has shown upward momentum, with its 50-day moving average at $40.20 and its longer-term 200-day moving average at $29.66. Because uniQure is still in its growth phase and focusing capital on research and development, it is not currently profitable. It has an earnings per share of -$4.03, meaning it does not have a meaningful price-to-earnings ratio.

12-month forecast

$QURE price target

uniQure N.V. daily closes and this analyst's $70 target. Not advice.

Recent Financial Results and Balance Sheet Strength

In its financial operations, uniQure recorded revenue of $18.67 million, achieving a revenue growth rate of 11.0% year-over-year. The company maintains a highly liquid balance sheet to fund its ongoing clinical trials. Its current ratio stands at 10.01, and its quick ratio is 9.79, indicating substantial short-term assets relative to its liabilities. The company's debt-to-equity ratio is 170.396.

Insider Buying and Selling at uniQure N.V.

Several key executives at uniQure have adjusted their holdings recently. On June 24, 2026, Chief Executive Officer Matthew Kapusta purchased 4,128 shares of company stock at an average price of $31.71 per share, a transaction totaling $130,898.88. On the very same day, Kapusta sold 6,696 shares at an average price of $50.00, totaling $334,800.00, under a pre-arranged Rule 10b5-1 trading plan.

Additionally, Chief Medical Officer Walid Abi-Saab sold 1,434 shares on June 26, 2026, at an average price of $46.86 per share, resulting in a total transaction value of $67,197.24. This transaction was not conducted under a planned trading program.

Wall Street Analysts Adjust Targets

Wall Street's broader analyst community has actively updated its assessments of uniQure. On October 5, 2026, Barclays downgraded the stock from an Overweight rating to an Equal-Weight rating, cutting its price target to $28.00 from a previous $60.00. Just a few days prior, on October 2, 2026, RBC Capital maintained its Outperform rating but adjusted its price target to $48.00 from $65.00.

Other summer updates include Goldman Sachs maintaining a Neutral rating on September 30, 2026, with a target of $31.00, down from $46.00. Conversely, Wells Fargo maintained an Overweight rating on July 30, 2026, and raised its target to $75.00. Wolfe Research upgraded the stock to Outperform on July 30, 2026, with a target of $65.00. HC Wainwright maintained its Buy rating on June 29, 2026, with an $80.00 target, while Mizuho kept an Outperform rating on June 25, 2026, raising its target to $68.00 from $35.00.

Currently, the consensus among 12 analyst opinions sits at a Strong Buy, with an average target price of $61.46.

About uniQure N.V.

uniQure N.V. is a biotechnology company based in Amsterdam, Netherlands. The firm focuses on genetic medicine, offering Hemgenix for patients with hemophilia B. It is also actively advancing clinical trials for therapies targeting temporal lobe epilepsy, amyotrophic lateral sclerosis, and Fabry disease.

Next Milestones to Watch

Investors tracking uniQure should look ahead to the company's next earnings announcement scheduled for November 9, 2026. Future regulatory updates regarding AMT-130 and Hemgenix commercialization will likely serve as key drivers for the stock's movement in the quarters ahead.